Mobile

A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplantat...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003970-89

A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplantation in whom iron overload is present

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate if ICL670 can provide clinically acceptable chelation, as measured by serum ferritin to patients presenting with iron overload three to six months after related or unrelated HCT (serum ferritin levels of ≥ 1000 ng/ml) irrespective of conditioning regimen.

Critère d'inclusion

  • allogeneic hematopoietic cell transplantation with iron overload

Liens